Jacob M. Kaufman
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
58
Citations
1,137
Est. group size
~15
Recurring co-author estimate
Active years
23
Publishing since 2003
Jacob M. Kaufman's research centers on non-small cell lung cancer (NSCLC), focusing on genetic mutations such as LKB1 and KRAS loss, how these alterations affect tumor biology and the immune system, and how patients respond to immune checkpoint blockade and other targeted therapies. The work combines clinical trial data, biomarker analysis, and computational methods to try to predict which patients will benefit from immunotherapy. This research aims to help clinicians better match lung cancer treatments to individual tumor genetics and immune characteristics.
Publication output was low and steady through the late 2010s and early 2020s, then spiked sharply in 2023 before settling into a moderate, still-elevated pace through 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis
Journal for ImmunoTherapy of Cancer · 2025
- A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer
Journal of Translational Medicine · 2024
- Functional Labeled Optimal Partitioning
Journal of Computational and Graphical Statistics · 2024
- A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer
UNC Libraries · 2024
- A Community Challenge to Predict Clinical Outcomes After Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
bioRxiv (Cold Spring Harbor Laboratory) · 2022
- Functional Labeled Optimal Partitioning
arXiv (Cornell University) · 2022
- 909 Differentiation subgroups within LKB1-deficient lung cancer influence both the immune exclusion phenotype and cellular composition of the immune microenvironment
Regular and Young Investigator Award Abstracts · 2021
- Interferon gamma resistance in setting of LKB1 loss: Phenotypic characterization and investigation of mechanism.
Journal of Clinical Oncology · 2020
- Association of NGS mutational pattern with immune checkpoint inhibitor clinical benefit in solid tumors.
Journal of Clinical Oncology · 2018
- Treatment of <i>KRAS-</i>Mutant Non–Small Cell Lung Cancer
JAMA · 2017
- P2.03b-069 LKB1 Loss is a Novel Determinant of MEK Sensitivity Due to Alterations in AKT/FOXO3 Signaling
Journal of Thoracic Oncology · 2017
- Abstract 2404: Dysregulation of lung developmental pathways associated with LKB1 loss in lung cancer
Cancer Research · 2016
- Abstract 4661: Loss of LKB1 in NSCLC confers sensitivity to MEK inhibition by regulating activation of AKT-FOXO3 pathway
Cancer Research · 2016
- Cancer Research×6
- Journal of Clinical Oncology×5
- Journal of Thoracic Oncology×3
- The Lancet Neurology×1
- Cancer Immunology Immunotherapy×1
- Zhen Qin
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Ziyu Liu
Biochemistry, Genetics and Molecular Biology · Indiana University
- Xiao Wang
Biochemistry, Genetics and Molecular Biology · Indiana University
- Nan Zhang
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Na Li
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile